Prenatal Tylenol & Leucovorin: Use Trends Rise

Following unsubstantiated claims made by former President Donald Trump in September 2025 linking acetaminophen (Tylenol) use during pregnancy to an increased risk of autism, data indicates a notable shift in medication practices. Orders for Tylenol among pregnant women visiting emergency departments have decreased, while prescriptions for leucovorin – a drug the Trump administration suggested as a potential autism treatment – have risen sharply. This confluence of changes, detailed in research published in The Lancet, highlights the powerful influence of public statements on healthcare decisions, even in the absence of robust scientific evidence.

The Backdrop: Trump’s September Announcement

On September 22nd, President Trump asserted a connection between Tylenol use during pregnancy and autism, prompting the Food and Drug Administration (FDA) to issue a communication to physicians regarding the matter. While the FDA’s letter acknowledged the topic as “an ongoing area of scientific debate,” Trump characterized Tylenol as a risk to be avoided. Simultaneously, he touted leucovorin (folinic acid) as “an exciting therapy” for children with autism. NBC News reported on the immediate fallout from these statements.

Observational Data Reveals a Shift in Practice

Researchers at Harvard Medical School and Brown University analyzed electronic health record data from Epic, examining Tylenol orders during emergency department visits and new leucovorin prescriptions in outpatient settings. Their analysis, covering data up to November 2025, revealed a 10% decrease in Tylenol orders for pregnant patients following Trump’s announcement. Notably, this decline wasn’t observed in non-pregnant women. The study, as reported by CIDRAP, suggests a direct correlation between the public statement and altered medication choices.

Understanding Acetaminophen and Pregnancy

Acetaminophen is a widely used pain reliever and fever reducer, often recommended as a first-line treatment during pregnancy. However, concerns have been raised in recent years regarding potential associations between acetaminophen exposure in utero and neurodevelopmental outcomes. It’s crucial to understand that these associations are largely based on observational studies, which can demonstrate correlation but cannot prove causation. The January 2026 analysis of existing research, referenced in the NBC News report, found no conclusive link between Tylenol use during pregnancy and neurodevelopmental disorders, including autism.

Leucovorin: A Drug with Limited Evidence for Autism

Leucovorin is a form of folic acid used to counteract the effects of certain medications, such as methotrexate. It’s also used to treat cerebral folate deficiency, a rare genetic condition. Trump’s suggestion that leucovorin could benefit children with autism was not supported by scientific evidence. As Dr. Jeremy Faust of Harvard Medical School pointed out in his Inside Medicine Substack, there is “simply no good evidence to suggest that it will help most children with autism or related conditions.” Despite this lack of evidence, the FDA updated its label to list leucovorin as a potential treatment for cerebral folate deficiency following Trump’s remarks.

The Challenge of Observational Studies

The researchers emphasize that their findings are based on observational data and cannot establish a causal relationship. Observational studies are susceptible to various biases and confounding factors. For example, the observed decrease in Tylenol orders could be attributed to increased awareness of potential risks, regardless of the validity of Trump’s claims. Similarly, the surge in leucovorin prescriptions may reflect parental anxiety and a desire to explore any potential treatment option, even in the absence of scientific support. Establishing causality would require rigorous, controlled clinical trials – which have not been conducted in this context.

What Does This Mean for Pregnant Women?

The current situation underscores the importance of relying on evidence-based medical advice from qualified healthcare professionals. Pregnant women experiencing pain or fever should discuss appropriate treatment options with their doctors, considering the benefits and risks of all available medications. The American College of Obstetricians and Gynecologists (ACOG) provides comprehensive guidance on medication use during pregnancy, which should be consulted in conjunction with a physician’s recommendations. ACOG’s website is a valuable resource for expectant mothers.

Navigating Uncertainty and Seeking Reliable Information

It’s understandable to feel anxious about medication use during pregnancy, especially when faced with conflicting information. The key is to prioritize credible sources of information and engage in open communication with your healthcare provider. Avoid relying on anecdotal evidence or unsubstantiated claims circulating on social media. Remember that medical guidance is constantly evolving as new research emerges, and your doctor is best equipped to provide personalized advice based on your individual circumstances.

Public Health Implications and Ongoing Monitoring

This episode highlights the potential for political statements to influence public health behaviors. The researchers suggest that ongoing monitoring of medication trends and public perceptions is crucial to assess the long-term impact of such events. Further research is needed to determine whether the observed changes in Tylenol and leucovorin use will have any measurable effects on maternal and child health outcomes. The FDA and other regulatory agencies will likely continue to evaluate the evidence regarding acetaminophen and autism, and update their guidance as appropriate.

Looking Ahead: Continued Surveillance and Evidence Evaluation

The FDA is expected to continue monitoring reports of adverse events related to acetaminophen use during pregnancy. Researchers are also planning to conduct further studies to investigate the potential link between acetaminophen exposure and neurodevelopmental outcomes, using more robust methodologies to address the limitations of observational studies. Public health officials will also be tracking trends in leucovorin prescriptions to assess whether the surge in demand is sustainable and whether it is associated with any unintended consequences.